← Back to Search

Antifibrinolytic Agent

Tranexamic Acid for Sarcoma

Phase 4
Waitlist Available
Led By Kyle Sweeney, MD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up postoperative days 1-3
Awards & highlights

Study Summary

This trial will test whether a drug called tranexamic acid reduces blood loss and the need for transfusions in patients undergoing surgery for musculoskeletal cancer.

Eligible Conditions
  • Soft Tissue Sarcoma
  • Musculoskeletal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~postoperative days 1-3
This trial's timeline: 3 weeks for screening, Varies for treatment, and postoperative days 1-3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Perioperative blood loss
Secondary outcome measures
Blood transfusion rates
Surgical drain output

Trial Design

4Treatment groups
Active Control
Group I: Bony tumor treated without TXAActive Control1 Intervention
This group of participants will undergo a bony tumor resection of the femur of proximal tibia and endoprosthetic reconstruction.
Group II: Soft tissue sarcoma treated without TXAActive Control1 Intervention
This group of participants will undergo soft tissue sarcoma resection of the lower extremity.
Group III: Bony tumor treated with Tranexamic acid (TXA)Active Control1 Intervention
This group of participants will undergo a bony tumor resection of the femur or proximal tibia and endoprosthetic reconstruction with TXA.
Group IV: Soft tissue sarcoma treated with Tranexamic Acid (TXA)Active Control1 Intervention
This group of participants will undergo soft tissue sarcoma resection of the lower extremity with TXA

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
460 Previous Clinical Trials
169,099 Total Patients Enrolled
Kyle Sweeney, MDPrincipal Investigator - University of Kansas Medical Center
University of Kansas Medical Center

Media Library

Tranexamic Acid (Antifibrinolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04347122 — Phase 4
Soft Tissue Sarcoma Research Study Groups: Bony tumor treated without TXA, Soft tissue sarcoma treated without TXA, Bony tumor treated with Tranexamic acid (TXA), Soft tissue sarcoma treated with Tranexamic Acid (TXA)
Soft Tissue Sarcoma Clinical Trial 2023: Tranexamic Acid Highlights & Side Effects. Trial Name: NCT04347122 — Phase 4
Tranexamic Acid (Antifibrinolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04347122 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open opportunities to join this clinical trial right now?

"The listing on clinicaltrials.gov reveals that the trial is actively seeking participants, with its first posting being published at January 28th 2020 and its most recent update taking place May 23rd 2022."

Answered by AI

Does the FDA sanction Tranexamic acid (TXA) for treating bone tumors?

"There is a wealth of clinical evidence backing the safety of Bony tumor treated with Tranexamic acid (TXA), which earned it a score 3 on our team's scale at Power. This treatment has passed Phase 4 trials, thus receiving approval for use."

Answered by AI

How does Tranexamic acid (TXA) therapy typically help those affected by bony tumors?

"Tranexamic acid (TXA) is typically administered to patients with hyperfibrinolysis. TXA also has a plethora of other applications, such as hemophilia management, abatement of bleeding episodes and aiding in tooth extractions."

Answered by AI

What is the cap for participants in this research endeavor?

"Affirmative. Clinicaltrials.gov reveals that the trial, which was initially posted on January 28th 2020, is actively recruiting patients. The total number of participants required for this study stands at 90 and will be sourced from a single testing centre."

Answered by AI

Could you elaborate on any other research initiatives concerning Bony tumors treated with Tranexamic acid (TXA)?

"Currently, 61 clinical trials researching Bony tumor treated with Tranexamic acid (TXA) are underway. Of these investigations, 26 have reached Phase 3 status and 185 different sites are involved in the research process. The majority of studies related to this medication originate from Kansas City, Kansas."

Answered by AI

Are geriatric individuals being incorporated into this trial's participant pool?

"This clinical trial has set out specific eligibility criteria, requiring participants to fall between the ages of 18-90. By comparison, 161 trials are available for minors and 417 studies cater to elderly individuals."

Answered by AI

To what extent are individuals eligible to partake in this medical experiment?

"This clinical trial requires 90 individuals with sarcoma, ranging from 18 to 90 years of age. In order to meet the admission criteria for this experiment, participants must be undergoing a wide resection of a malignant bony tumor in their lower extremity or have had soft tissue sarcomas measuring more than five centimeters removed."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction
Kyle Sweeney, MD 2020. "Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04347122.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top